Orchestra BioMed (OBIO) Projected to Post Earnings on Wednesday

Posted by ABMN Staff on Mar 19th, 2025

Orchestra BioMed (NASDAQ:OBIO – Get Free Report) is projected to release its earnings data before the market opens on Wednesday, March 26th. Analysts expect Orchestra BioMed to post earnings of ($0.43) per share for the quarter.

Orchestra BioMed Price Performance

Shares of OBIO stock opened at $4.05 on Wednesday. Orchestra BioMed has a 12 month low of $3.75 and a 12 month high of $8.87. The firm has a market capitalization of $153.96 million, a P/E ratio of -2.52 and a beta of 0.59. The company’s fifty day moving average price is $5.04 and its two-hundred day moving average price is $5.25.

Institutional Investors Weigh In On Orchestra BioMed

A hedge fund recently raised its stake in Orchestra BioMed stock. Bank of America Corp DE lifted its holdings in shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO – Free Report) by 42.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 23,780 shares of the company’s stock after buying an additional 7,036 shares during the period. Bank of America Corp DE owned 0.06% of Orchestra BioMed worth $95,000 at the end of the most recent reporting period. 53.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on OBIO. HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Orchestra BioMed in a research report on Monday, March 10th. Barclays began coverage on shares of Orchestra BioMed in a research report on Thursday, January 2nd. They issued an “overweight” rating and a $16.00 target price for the company.

View Our Latest Stock Report on OBIO

About Orchestra BioMed

(Get Free Report)

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.